OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Gong on the Current Treatment Armamentarium in mHSPC

February 7th 2024

Jun Gong, MD, discusses the current treatment armamentarium for patients with metastatic hormone-sensitive prostate cancer.

Dr Olazagasti on a Case-Based Discussion of ALK-Mutated NSCLC Treatment

February 6th 2024

Coral Olazagasti, MD, discusses her participation in a case-based discussion at the 21st Annual Winter Lung Cancer Conference®.

Dr Rosner on Personalizing Approaches to Perioperative Therapy in NSCLC

February 6th 2024

Samuel Rosner, MD, discusses ongoing efforts to individualize the use of perioperative/neoadjuvant therapy in early-stage NSCLC.

Dr Smith on the Rationale for Investigating the Predictive Utility of CA-125 KELIM Score in Ovarian Cancer

February 6th 2024

Gabriella Smith, MD, discussed the predictive value of CA-125 KELIM score for survival outcomes with HIPEC during surgery in epithelial ovarian cancer.

Dr Mikhael on the Importance of Disparities Research in Multiple Myeloma

February 6th 2024

Joseph Mikhael, MD, discusses the importance of researching disparities in treatment outcomes for patients with multiple myeloma.

Dr Jain on Results From the COMMANDS Trial in Lower-Risk MDS

February 6th 2024

Akriti Jain, MD, discusses the outcomes of the phase 3 COMMANDS trial in transfusion-dependent lower-risk myelodysplastic syndromes.

Dr McGregor on Sacituzumab Govitecan Plus Enfortumab Vedotin in Treatment-Resistant mUC

February 5th 2024

Bradley McGregor, MD, discusses the next steps for investigating cabozantinib plus atezolizumab in patients with advanced renal cell carcinoma.

Dr Sammons on the Real-World Incidence of Brain Metastases in HER2+ Breast Cancer

February 5th 2024

Sarah Sammons, MD, discusses the real-world incidence of brain metastases in HER2-positive breast cancer per line of treatment as well as cumulatively.

Dr Mikhael on Unmet Needs in Cancer Care for Patients With Multiple Myeloma

February 4th 2024

Joseph Mikhael, MD, discusses the importance of closing gaps in care for patients with multiple myeloma in underserved populations.

Dr Halmos on Treatment Strategies For EGFR-Mutant NSCLC

February 4th 2024

Balazs Halmos, MD, discusses treatment strategies for patients with EGFR-mutant non–small cell lung cancer.

Dr Siegel on the Importance of Closing the Gaps in Cancer Care

February 4th 2024

David Samuel Dicapua Siegel, MD, discusses the importance of closing the gaps in cancer care and spreading awareness of current treatment inequities in oncology through campaigns such as World Cancer Day.

Dr Curran on Developing Strategies for Stage III NSCLC Management

February 4th 2024

Wally Curran, MD, discusses current and developing treatment strategies for patients with stage III unresectable non–small cell lung cancer.

Dr Simon on the Utility of Novel Treatments in Diverse Patient Populations With Cancer

February 4th 2024

George Simon, MD, FACP, FCCP, discusses the importance of enrolling diverse patient populations in cancer clinical trials.

Dr Levy on Unanswered Questions Regarding the Mechanism of Action of ADCs in NSCLC

February 3rd 2024

Benjamin Levy, MD, discusses the mechanism of action of antibody-drug conjugates in patients with non–small cell lung cancer.

Dr Leal on the Development of DLL3-Targeted Agents in SCLC

February 3rd 2024

Ticiana Leal, MD, discusses the variety of DLL3-targeted agents in development for patients with small cell lung cancer and neuroendocrine tumors.

Dr Pellini on the Development of Increasingly Sensitive ctDNA Assays in NSCLC

February 3rd 2024

Bruna Pellini, MD, discusses the importance of developing circulating tumor DNA assays with increased sensitivity.

Dr Rodriguez on the Use of HER2-Directed Therapies in NSCLC

February 3rd 2024

Estelamari Rodriguez, MD, MPH, discusses adverse effects associated with HER2-directed antibody-drug conjugates in non–small cell lung cancer.

Dr George on the CheckMate 8Y8 Trial of Nivolumab With/Without Ipilimumab in Untreated RCC

February 2nd 2024

Daniel J. George, MD, discusses the phase 3b CheckMate 8Y8 study of nivolumab plus ipilimumab vs nivolumab alone in previously untreated advanced RCC

Dr Castillo on Acalabrutinib Plus Rituximab in Patients With Anti-MAG IgM Peripheral Neuropathy

February 2nd 2024

Jorge J. Castillo, MD, discusses preliminary data from a phase 2 study of acalabrutinib plus rituximab in patients with IgM symptomatic anti-MAG peripheral neuropathy.

Dr Yu discusses the ARCAD Nomogram in a Real-World CRC Population

February 2nd 2024

James Yu, MD, discusses the validation of the ARCAD nomogram in the real-world setting for patients with stage IV colorectal cancer.